toxylact: a05ab52 dimenhyrinat combinations
The first professional lActological database in the word
Dimenhydrinate combinations (ATC A04AB52) are sedating first‑generation antihistamine antiemetics used orally for prevention and treatment of motion sickness–related nausea, vomiting and vertigo, sometimes with additional benefit in allergic symptoms.medpedia.framar
ATC class and pharmacological profile
ATC A04AB52 comprises fixed combinations containing dimenhydrinate, classified under antiemetics and drugs against nausea (A04), antihistamines subgroup (A04AB). Dimenhydrinate itself is a salt of diphenhydramine and 8‑chlorotheophylline, exerting H1‑antihistamine, anticholinergic and vestibular‑suppressant effects, and the combinations may include other antiemetics or adjuncts depending on the product.medpedia.framar
Indications and clinical use
Dimenhydrinate combinations are indicated for prophylaxis and treatment of nausea, vomiting and dizziness associated with motion sickness and other vestibular disorders. In clinical practice they are also used off‑label for various nausea syndromes and may relieve concomitant allergic manifestations due to their antihistamine activity.medpedia.framar
Dosage regimen and administration
The usual oral daily dose range for dimenhydrinate combinations is 50–400 mg divided into 2–3 administrations per day, adjusted according to age, clinical response and product composition. Preparations are prescription‑only and should be used for the shortest duration compatible with symptom control, particularly in vulnerable populations such as children and lactating women.medpedia.framar
General adverse effects (toxicological profile)
Adverse reactions are largely dose‑dependent and related to central H1‑blockade and anticholinergic activity, with prominent CNS and autonomic effects. Commonly reported reactions include somnolence, dizziness, irritability, tremor, insomnia, increased excitability, impaired coordination, convulsions, rash, sweating, photosensitivity, hypotension, cardiac rhythm disturbances, dry mouth, epigastric pain, nausea, vomiting, diarrhoea, constipation, loss of appetite, nasal and pharyngeal dryness, nasal congestion and urinary disturbances.medpedia.framar
Toxicological risk considerations
From a toxicological perspective, the major risks with dimenhydrinate combinations are CNS depression (or paradoxical excitation in children), anticholinergic toxicity and cardiovascular effects. High doses or predisposition (e.g. epilepsy, arrhythmias, glaucoma, prostatic hypertrophy) increase the likelihood of severe neurological events (including seizures), urinary retention or decompensation of cardiovascular status, and combination products may further modulate this risk profile depending on co‑components.medpedia.framar
Contraindications and high‑risk conditions
Use of dimenhydrinate combinations is contraindicated in hypersensitivity to the product, concurrent treatment with monoamine oxidase (MAO) inhibitors, acute asthmatic attack, elevated intraocular pressure (e.g. narrow‑angle glaucoma), pheochromocytoma, porphyria, prostatic hypertrophy and seizure disorders such as epilepsy and eclampsia. In these settings the anticholinergic and sympathomimetic components may precipitate bronchospasm, glaucoma crisis, hypertensive or catecholamine surge events, porphyric attacks, urinary retention or seizures, and safer alternative antiemetics should be preferred.medpedia.framar
Lactation safety considerations
For toxicological‑lactological assessment, the class is characterised by:
- Potential transfer into breast milk of sedating H1‑antihistamines and any co‑formulated drugs, raising concern for infant sedation, irritability or feeding difficulties.
- Anticholinergic effects that may theoretically reduce maternal milk let‑down or contribute to maternal side effects impacting breastfeeding.
Given the sedative, anticholinergic and pro‑convulsive profile described, prolonged or high‑dose exposure during lactation warrants caution, prioritising short‑term use at the lowest effective dose when there is a clear clinical need and no safer antiemetic alternative. Breastfed infants should be monitored for excessive drowsiness, paradoxical agitation, poor suck and inadequate weight gain, and in high‑risk neonates or preterm infants, non‑sedating or non‑antihistaminic antiemetics are generally preferable.medpedia.framar
Practical toxicological‑lactological recommendations
In the context of a specialist database for healthcare professionals, dimenhydrinate combinations (A04AB52) may be characterised as:
- Use in lactation: generally not preferred for routine or long‑term therapy; short‑course use may be acceptable with careful benefit–risk assessment and infant monitoring.
- Maternal risk: relevant CNS and anticholinergic toxicity at higher doses or in predisposed patients; strict adherence to dosing recommendations and contraindications is essential.medpedia.framar
- Infant risk: potential sedation, feeding impairment and rare paradoxical excitation; increased vigilance is required when mother receives sedating antihistamines.medpedia.framar
Clinical decision‑making should integrate maternal indication (e.g. severe motion sickness), available alternatives, infant age and comorbidities, and product‑specific combination components, rather than considering dimenhydrinate combinations as first‑line agents in nursing women.
Regulatory and access information
Dimenhydrinate combination products within ATC A04AB52 are dispensed on medical prescription, underscoring their classification as medicines requiring professional supervision. Prescribers should document indication, dosing and counselling about sedation, driving and breastfeeding, and pharmacists should reinforce guidance to avoid concomitant CNS depressants and MAO inhibitors.medpedia.framar



